ABSTRACT BACKGROUND: Previously, we identified four depression subtypes defined by distinct functional connectivity alterations in depression-related brain networks, which in turn predicted clinical symptoms and treatment response. Optogenetic functional magnetic resonance imaging offers a promising approach for testing how dysfunction in specific circuits gives rise to subtype-specific, depression-related behaviors. However, this approach assumes that there are robust, reproducible correlations between functional connectivity and depressive symptoms-an assumption that was not extensively tested in previous work. METHODS: First, we comprehensively reevaluated the stability of canonical correlations between functional connectivity and symptoms (N = 220 subjects) using optimized approaches for large-scale statistical hypothesis testing, and we validated methods for improving estimation of latent variables driving brain-behavior correlations. Having confirmed this necessary condition, we reviewed recent advances in optogenetic functional magnetic resonance imaging and illustrated one approach to formulating hypotheses regarding latent subtype-specific circuit mechanisms and testing them in animal models. RESULTS: Correlations between connectivity features and clinical symptoms were robustly significant, and canonical correlation analysis solutions tested repeatedly on held-out data generalized. However, they were sensitive to data quality, preprocessing, and clinical heterogeneity, which can reduce effect sizes. Generalization could be markedly improved by adding L2 regularization, which decreased estimator variance, increased canonical correlations in left-out data, and stabilized feature selection. These improvements were useful for identifying candidate circuits for optogenetic interrogation in animal models. CONCLUSIONS: Multiview, latent-variable approaches such as canonical correlation analysis offer a conceptually useful framework for discovering stable patient subtypes by synthesizing multiple clinical and functional measures. Optogenetic functional magnetic resonance imaging holds promise for testing hypotheses regarding latent, subtype-specific mechanisms driving depressive symptoms and behaviors.
connectivity alterations in specific circuits mediate particular symptoms and behaviors. Addressing this issue will require new approaches aimed at "bridging the causality gap" (33) by experimentally manipulating specific circuits and testing for effects on behavior.
The primary goal of the present work was to illustrate one such approach to formulating hypotheses regarding subtypespecific circuit mechanisms driving depressive behaviors in patients and then testing homologues in animal models using optogenetic functional magnetic resonance imaging (ofMRI). Importantly, this approach assumes that RSFC alterations capture an important latent component of depression pathophysiology that reliably predicts symptoms and behavior. However, a recent preprint study raised questions about this central assumption by showing that CCA involving highdimensional neuroimaging data tends to overfit and suggesting that RSFC-behavior correlations may not be reliable (34) . Thus, a necessary prior goal was to test the assumption that we can reliably reproduce latent variables underlying RSFC-behavior correlations.
We begin by comprehensively reevaluating whether RSFC alterations are stably related to depressive symptoms using optimized approaches for large-scale statistical testing. We find that correlations between RSFC features and clinical symptoms are robustly significant and, further, that latent variable (CCA) solutions tested repeatedly on held-out data generalize, but tend to overfit with increasing numbers of features. To overcome this obstacle, we show that generalization can be markedly improved by adding L2 regularization. Having confirmed these key assumptions, we review recent advances in ofMRI and illustrate how it could be used to causally interrogate latent subtype-specific circuit mechanisms driving particular depression-related behaviors, integrating results from our recent subtyping work with published ofMRI studies. We also discuss pros and cons of this method, relative to lesion analyses and noninvasive brain stimulation methods that can be applied directly in humans.
METHODS AND MATERIALS Subjects
The analyses reported in Figures 1-3 were designed to reevaluate our approach in our previous work (18) using stateof-the-art statistical methods to test whether depressionrelated RSFC alterations are significant and stable predictors of clinical symptoms. Therefore, these analyses were conducted in the same subtype-discovery sample used in Drysdale et al. (18) , which comprised 220 subjects meeting DSM-IV criteria for a diagnosis of (unipolar) major depressive disorder (MDD) and currently experiencing an active, nonpsychotic major depressive episode at the time of the fMRI scan (see Table 1 for details). In addition, to better understand whether differences between this sample (summarized in Supplemental Table S1 ) and the sample used in Dinga et al. (34) may have influenced their power to detect statistically significant RSFC-clinical symptom correlations, we conducted supplementary analyses in a separate sample of 184 subjects (acquired during ongoing studies at Weill Cornell Medicine and Toronto Western Hospital) that more closely resembles their dataset. See Supplemental Methods for further details on subjects and MRI data acquisition.
fMRI Data Preprocessing and RSFC Quantification
Preprocessing was identical to the procedure defined in our previous report (18) and is described in Supplemental Methods.
Data Analysis
The stability and significance of correlations between RSFC features and Hamilton Rating Scale for Depression (HAMD) clinical symptoms was assessed by calculating the 33, 123 Pearson correlation coefficients (PCCs) between each RSFC feature and each of 16 of the HAMD item-level measures on 1000 bootstrap replicates to estimate the variance of these correlations (item 17 was excluded, having zero variance in many replicates). We then followed the procedure of Efron (35) , using correlation-corrected z values and bootstrapping to calculate the percentage of correlations that exceeded chance level. See Supplemental Methods for further details.
CCA (36, 37) was performed between clinical measures and a selected subset of screened RSFC features (those with highest Spearman correlation) as previously described (18) . Owing to this feature screening step, we used validation on held-out data in subsequent analyses to avoid overly optimistic correlation estimates due to training-set overfitting. To better stabilize CCA coefficients, L2-regularized CCA (38) was also applied. This approach uses two regularization parameters, l X and l Y , to regularize the estimated covariance matrices for the RSFC and clinical features, respectively. To find the best combination of these two variables, a grid search over possible values of the parameters and number of features was conducted, with 1000 regularized CCA (RCCA) fits found for each parameter combination. For each set of parameters, model fitting was done on training data and then assessed via the magnitude of the first canonical correlation coefficient on held-out validation test data, using the same procedure as above for standard CCA. See Supplement for further details.
RESULTS

Testing for Robust Correlations Between RSFC Features and Clinical Symptoms
We began with a modern approach to a classical problem: establishing the existence and strength of correlations between brain and behavior using mass univariate statistics. Examining number, strength, and effect size of these correlations gives us a strong basis from which to begin more complicated multivariate analyses (such as CCA) and convinces us of the utility of doing so. Furthermore, understanding the structure of univariate correlations between RSFC and clinical symptoms gives us insight into what kind of challenges might present themselves in the multivariate setting. First, we correlated each RSFC feature with each HAMD clinical symptom and estimated the number of z values for the resulting RSFC-symptom PCCs that exceeded the threshold of significance expected by chance (Figure 1 Supplemental Methods). We were also interested in establishing the variance of the number of significant correlations: Is it stable, or do small changes in the data collection conditions translate to large changes in the number of correlations that are found to be significant (indicating unstable correlation estimates)?
To estimate the variance of the number of correlations above the significance threshold, we used the bootstrap (39), resampling the RSFC and clinical data for each subject to generate 1000 bootstrap replicate datasets, and then ran the z value procedure from Efron (35) on each. A representative result for HAMD item 1 (HAMD 1: depressed mood) is shown in Figure 1A , with the shaded region showing the number of significant RSFC feature-HAMD 1 correlations above the number expected by chance. We generated confidence intervals for the significant z value estimates with the percentile bootstrap and corrected for the 16 multiple comparisons across the HAMD clinical features using the Holm-Bonferroni procedure, yielding the results shown in Figure 1B , with effect sizes in Figure 1C (40) . Seven HAMD measures had median significant percentages (number , with mean 95% confidence intervals 6 SD of 0.148 6 0.0152, 0.376 6 0.0119]. Note these look very similar, suggesting the rank order could easily change across replicates. Symptom abbreviations: Anergia, also encompasses somatic symptoms; Anhedonia, also encompasses work activities; GI, gastrointestinal symptoms; Hypochond., hypochondriasis; Mid., middle insomnia; Phys, physiological anxiety symptoms; PMA, psychomotor agitation; PMR, psychomotor retardation; Psych, psychological anxiety symptoms; Weight, weight loss or weight gain.
ofMRI for Defining Circuit Mechanisms in Depression Violin plots (with superimposed boxplots) of correlations between the first canonical variate (CV1) of a standard canonical correlation analysis (CCA) on training data (90% of subjects) and test data (10% of subjects) for a range of features by increments of 10) selected using the correlation method proposed in Drysdale et al. (18) , with this procedure bootstrapped 1000 times for each number of features to yield the plotted distributions. Feature selection and CCA fitting were done on training data separately for each bootstrap replicate, and then estimated CCA coefficients were applied to the selected features in the held-out validation set to obtain test correlations. Test correlations for CCA peak at 20 features selected. Black arrow shows standard CCA cannot be fit to more correlations than there are observations (in this case 90% of N = 220, or 198 subjects). We also examined the range of RSFC-HAMD correlations. Figure 1D shows the 1000 most positive (left panel) and 1000 most negative (right panel) correlations, ordered by the average PCC across bootstrap replicates (solid blue line), with 95% confidence intervals (percentile bootstrap). All of the 1000 most positive PCCs and a substantial fraction of the 1000 most negative PCCs had confidence intervals excluding zero, but there was also a significant range over which different bootstrap replicates might yield different orderings of the coefficients. This is illustrated in Figure 1E , showing violin plots detailing the distribution of PCCs for the 10 most positive PCCs: The distributions were significantly different from zero but looked relatively exchangeable, such that their ranking would change over bootstrap replicates. Thus, a large number of very similar variables could result in highly variable feature selection, with implications for CCA discussed below.
RSFC-Clinical Symptom Correlations Are Sensitive to Clinical Sampling and Preprocessing Decisions
Dinga et al. in a recent preprint (34) reported the results of an analysis similar to our earlier work (18) and concluded that RSFC-clinical symptom correlations were not significant, which would seem to contradict the findings reported in Figure 1 . However, there were several important differences between these two studies (see Supplemental Table S1 for details), especially in their clinical sample characteristics and preprocessing pipelines. Of note, the sample in Dinga et al. (34) included 187 subjects scanned on four different scanners (vs. 220 subjects scanned on just two scanners in our previous work, yielding a larger number of subjects per scanner and potentially more stable corrections for scanner-related differences). Among other differences, Dinga et al. (34) did = Figure 3 . Optogenetic functional magnetic resonance imaging (fMRI) for interrogating subtype-specific circuit mechanisms in depression. (A) Schematic illustration of a model for formulating hypotheses regarding subtype-specific mechanisms driving depressive symptoms and behaviors and testing them in animal models using optogenetic fMRI. By first testing for robust and stable resting-state functional connectivity (RSFC)-clinical symptom correlations as in Figure 1 and then using canonical correlation analysis (CCA) and hierarchical clustering, relatively homogeneous subgroups of a heterogeneous major depressive disorder sample can be identified. These subgroups can be used to identify subtype-specific candidate circuits (see text), and optogenetic fMRI can be used to test hypotheses about dysfunction in specific circuits driving specific behaviors, while also validating whether the RSFC effects evoked by the optogenetic manipulation resemble those observed in human subjects. ) driving SSFO expression in projection neurons was injected into medial prefrontal cortex (mPFC), and an optical fiber implanted over the mPFC target was used to activate (blue light) and inactivate (amber light) the opsin during alternating resting-state fMRI scanning periods (300 seconds per scan). SSFO activation induced a pattern of increased functional connectivity between an mPFC seed (denoted by the red dot) and a network of structures depicted here, where colors denote the Z statistic (and associated p value) for RSFC changes in the opsin-on vs. opsin-off conditions (n = 4 rats, 14 runs). (F) Subjects (n = 8 SSFO rats, blue; n = 10 control rats, black) were assessed on the sucrose preference test during a 2-day baseline period, followed by 6 days with SSFO activated, followed by a 4-day washout period with SSFO off. SSFO activation reduced sucrose preference behavior ( The analyses in Figures 1-3 were implemented in the same dataset used in Drysdale et al. (18) . Subjects recruited at the Toronto and Cornell sites were matched for age (p = .41), gender (p = .87), and depression severity (HAMD-17 total score, p = .11).
HAMD-17, 17-item Hamilton Rating Scale for Depression.
a Psychiatric medications listed as "Other" included benzodiazepines, nonbenzodiazepine sedative-hypnotics, stimulants, and thyroid hormone. Psychiatric comorbidities listed as "Other" included obsessivecompulsive disorder, attention-deficit/hyperactivity disorder, Asperger's disorder, and Tourette's syndrome.
ofMRI for Defining Circuit Mechanisms in Depression not directly control for scanner-related differences, and their sample was also more clinically heterogeneous (including MDD, generalized anxiety disorder, social phobia, or panic disorder with no specified requirements for active depressive symptoms vs. currently active, treatment-resistant MDD in our work). By testing for RSFC-clinical symptom correlations in this more heterogeneous sample, the approach in Dinga et al. (34) assumes that the mechanisms driving these correlations are the same across these disorders, but this may not be true. For example, it is possible that different mechanisms may drive anxiety symptoms in MDD compared with panic disorder, in which case an analysis of subjects with mixed diagnoses could yield smaller effect sizes and unstable results in held-out data.
To test whether these clinical sample and preprocessing differences could influence their power to detect robust RSFCclinical symptom correlations, we repeated the analysis reported in Figure 1 in a second, more clinically heterogeneous sample of 184 subjects with MDD or an anxiety disorder, scanned on one of four scanners, and preprocessed exactly as in Dinga et al. (34) (see Supplemental Methods). The results in Supplemental Figure S1 show that small but statistically significant RSFC-clinical symptom correlations are still detectable for 10 of 16 symptoms (vs. 14 of 16 in Figure 1B ), but these associations are modest, with uniformly small effect sizes (d = 0.21-0.29 for 5 symptoms, d , 0.2 for all others). These results are consistent with the interpretation that distinct mechanisms give rise to RSFC-clinical symptom correlations across these heterogeneous disorders and that preprocessing decisions may be important.
Stable Canonical Correlations Between RSFC Features and Clinical Symptoms
CCA (36,37) is a classical multiview statistical approach that we (18) and others (21) have used to find latent linear combinations of RSFC measures and clinical features (canonical variates) that are maximally correlated with each other. In principle, CCA is a potentially useful approach for discovering subtypes of depression (or a dimensional rating system) anchored in brain network dysfunction and for identifying potential latent targets for optogenetic and other causal investigations: It provides a generalizable, low-dimensional representation of the relationship between neuroimaging and clinical features in the form of a simplified summary of the interesting structure between them. However, traditional CCA has some potential weaknesses, particularly on largescale, correlated data. In particular, CCA coefficients become unstable in the presence of multicollinearity (i.e., significant correlations between variables, as we might suspect between RSFC features and HAMD symptoms) (38) . Further, CCA can operate on only as many variables as there are observations, so that feature selection is necessary before applying CCA to reduce the 33,123 RSFC measures to a number less than or equal to the number of subjects in the study (38) . Despite this, CCA yielded promising results in recent studies (21) and in the data presented in our previous work (18) . However, the stability of CCA solutions was not integral to the other analyses in our previous study (18) and thus was not directly assessed.
To test this, we resampled the data 1000 times (without replacement) into training (90% of subjects) and validation (test) sets (the remaining 10%) and assessed CCA stability by comparing the resulting canonical correlations in the first canonical variate subspace across increasing numbers of RSFC features (Supplemental Methods). Figure 2A shows that standard CCA overfits: The training correlations gradually approached 0.9, whereas the test correlations increased initially but then decreased toward 0.1. The variance of the distributions for test canonical correlations was large, but the best fit had a median canonical correlation of 0.557 (interquartile range = 0.456-0.642), suggesting that the approach is promising.
We hypothesized that these results might be stabilized via L2 regularization applied to the CCA coefficients associated with both the RSFC and the clinical features, as both were multicollinear. L2 regularization [the ridge penalty (41)] induces a small downward bias in coefficient magnitude in exchange for a potentially large reduction in coefficient variance (42) . In RCCA, we shrink the sample covariance matrix both for the RSFC features c P X and for the clinical measures c P Y toward the identity matrix by replacing them with c P X 1 l X I and c (38) . This requires specifying the value of the two regularization parameters l X and l Y for each RCCA fit. To assess the effects of these parameters on fit quality, we fit each of our RCCA models over a grid of l X and l Y , with each parameter taking values in set f0; 0:1; 1; 10; 100; 1000; 1e6; 1e9g. Figure 2B depicts the median canonical correlation results on the held-out test data (over 1000 replicates) and shows that a small amount of regularization of the RSFC feature coefficients greatly improved the test canonical correlations. To a lesser extent, regularization of the HAMD coefficients also benefits fit, with a peak median test canonical correlation at l X ¼ 0:1 and l Y ¼ 1:0 of 0.735 (interquartile range = 0.665-0.797). Compared with the CCA fit in Figure 2A , the test canonical correlations for the best RCCA (fit at l X ¼ 0:1; l Y ¼ 1:0) had lower variance, remained above zero, and improved with increasing number of features ( Figure 2C, D) . Furthermore, if we examine the stability of test correlations between additional canonical variates ( Figure 2E) , we see that RCCA uniformly outperforms CCA (at its best performance at 20 RSFC features) for the first four sets of canonical variates. Thus, regularization of both RSFC and HAMD feature coefficients stabilizes and improves low-dimensional coembedding of neuroimaging and clinical measures.
As noted above, Figure 1D showed that a large number of very similar variables could result in highly variable feature selection across bootstrap replicates. Figure 2F and G show the ranked distributions of which RSFC features were chosen by the screening procedure over the 1000 subsamples when selecting the top 20 features (the optimum for traditional CCA in Figure 2A ) versus the top 160 features (the optimum for RCCA in Figure 2C ). Having just 20 RSFC features ( Figure 2F ) means just three features are selected more than 80% of the time, whereas having 160 features results in 25 features appearing more than 80% of the time. In Figure 2H , we ran pairwise comparisons looking at how many features appeared in both of two replicates (randomly choosing 100 of the subsample replicates) and found that the number of consistently ofMRI for Defining Circuit Mechanisms in Depression selected features increased linearly with the total number of features selected. Thus, stabilizing CCA with regularization allows the model to leverage more features than standard CCA, yielding a broader set of more reliable features that result in higher out-of-sample test correlations.
DISCUSSION
Together, these results support the hypothesis that RSFC alterations capture an important component of the pathophysiology of depression and are robust and reliable predictors of specific symptoms in actively depressed patients with MDD. In particular, as shown in our previous work (18) , CCA in this sample revealed two canonical variates, predicting individual differences in 1) anhedonia and psychomotor slowing (HAMD items 7 and 8) and 2) anxiety and insomnia (HAMD items 4, 5, and 11). Individual patients, in turn, could be clustered into subgroups defined by relatively homogeneous patterns of altered functional connectivity in these two dimensions, which predicted distinct clinical symptom and treatment response profiles (Figure 3 ) (18) . Other groups have reported similarly promising results for parsing diagnostic heterogeneity based on task-related and resting-state fMRI (rsfMRI), clinical symptoms, and neuropsychological profiles in affective disorders (19) (20) (21) (22) as well as in psychosis and attention-deficit/ hyperactivity disorder (12, (43) (44) (45) . For example, Price et al. (19) identified two sexually dimorphic subgroups of patients with depression that differed with respect to RSFC in the default mode network and predicted individual differences in comorbid anxiety and history of recurrence. More recently, Xia et al. (21) used sparse CCA in a sample of 663 youths with mixed diagnoses to identify four dimensions of altered functional connectivity predicting mood symptoms, psychosis, fear, and externalizing behavior. Importantly, they went on to replicate these findings in an independent sample of 336 subjects, providing further support for the assumption that stable latent-variable relationships between RSFC and clinical symptoms could be used to develop more biologically homogeneous diagnostic labels.
In all of these studies, it remains unclear whether RSFC alterations reflect changes in specific circuits driving depression-related behaviors or are merely correlated with them. Optogenetic tools offer one approach to addressing this question. Over the last 10 years, optogenetic studies have begun to define causal relationships between circuit function and behavior (46) (47) (48) (49) (50) (51) , with important implications for both neurological (52-54) and psychiatric (49, (55) (56) (57) (58) (59) (60) (61) diseases. Importantly, these methods can also be integrated with fMRI and other noninvasive neuroimaging techniques that are widely used in humans, offering new opportunities for testing hypotheses and predictions derived from human neuroimaging studies (55, 62) . Below, we review these developments, illustrate one model for testing such hypotheses, and discuss important caveats and limitations relative to other approaches.
ofMRI for Testing Subtype-Specific Circuit Mechanisms in Depression
First introduced in 2010 (62), ofMRI combines high-field fMRI with photoactivatable opsins to manipulate the activity of genetically defined cellular subtypes and test for local and global effects on neuronal activity and brain network function. The initial report by Lee et al. (62) underscored two of the most important and commonly implemented applications of ofMRI. First, it showed how ofMRI could be used to glean mechanistic insights into the neurophysiological basis of the fMRI blood oxygen level-dependent (BOLD) signal-a critical issue for interpreting the results of clinical neuroimaging studies. This report (62) showed that optogenetic stimulation of neocortical or thalamic excitatory neurons was sufficient to drive local BOLD signal responses, informing an ongoing debate about the nature of the neuronal signals and cellular subtypes that underlie the BOLD signal. Subsequent ofMRI studies showed that the BOLD signal is more strongly correlated with local spiking activity than with the local field potential (63) and is driven by the effects of neuronal activity on cerebral venules (64) . Recent studies have also shown how inhibitory interneurons and astrocytes contribute to the BOLD signal, independently of activity in excitatory pyramidal neurons and through distinct mechanisms (65, 66) . Second, Lee et al. (62) showed how ofMRI could be used for whole-brain functional circuit mapping, by optogenetically manipulating the activity of excitatory pyramidal cells in a specific brain area and testing for downstream BOLD signal effects. More recent studies extended this approach to map the functional networks activated by specific circuits (e.g., dorsal vs. ventral hippocampus) (67) (68) (69) (70) (71) (72) and by specific cellular subtypes (e.g., dopaminergic vs. glutamatergic cells in the ventral tegmental area [VTA] ; serotonergic responses to fluoxetine and acute stress) (73) (74) (75) (76) , often with surprising results that could not be predicted based solely on mapping the axonal projection fields of a given brain region (71, 76) . Other studies are defining new methods for integrating ofMRI with two-photon microscopy and head-fixed behavior (77, 78) .
Of particular relevance for translational neuroscience studies, ofMRI methods can also be used to recapitulate disease-related pathophysiological processes and evaluate their impact on brain networks and behavior. To this end, we illustrate one approach for formulating hypotheses regarding subtype-specific mechanisms driving depression-related behaviors and testing them in animal models using ofMRI ( Figure 3A) , drawing on two recently published works. In this model, rsfMRI is used to identify candidate circuits that predict specific symptoms and behaviors in patients. ofMRI, in turn, can be used to recapitulate and validate these connectivity changes in functionally related circuits in rodents and test for causal effects on associated behaviors. One approach to identifying promising candidate circuits involves searching for connectivity alterations and clinical symptoms that tend to cooccur. For example, in our previous work (18) , hierarchical clustering on the two canonical variates described above revealed at least four clusters or subtypes ( Figure 3B ), predicting group differences in multiple symptoms, especially anhedonia and anxiety ( Figure 3C ). Group differences in anhedonia and anxiety, in turn, were associated with functional differences in depression-related brain networks ( Figure 3D ).
These subtype-specific patterns were complex; however, qualitatively, two observations stood out. First, subtypes 1 and 4 were associated with increased anxiety and connectivity deficits in frontoamygdala circuits ( Figure 3D [79] [80] [81] [82] . Second, subtypes 3 and 4 were associated with increased anhedonia and hyperconnectivity between the medial prefrontal cortex (mPFC), ventral striatum, and other frontostriatal circuits that have been implicated in reward processing, effort valuation, and motivation (6, 27, (83) (84) (85) (86) (87) (88) (89) .
Optogenetic tools provide one means of testing whether altering functional connectivity in these circuits is sufficient for driving specific depression-related behaviors. Stable step function opsins (SSFOs) are particularly useful in this context, in that they were designed to achieve stable, partial depolarization on a timescale of minutes (49), suitable for use in rsfMRI analyses of low-frequency signal fluctuations, but still immediately reversible, enabling within-subject statistical comparisons. Furthermore, by partially depolarizing neurons and rendering them responsive to their physiological inputs, they can, in principle, be used to reversibly modulate functional connectivity in specific circuits and cell types.
A recent ofMRI study by Ferenczi et al. (55) provides evidence consistent with the hypothesis that increased functional connectivity in a specific frontostriatal network, qualitatively similar to the pattern observed in subtypes 3 and 4, is sufficient to drive anhedonic behavior in rats. In this study, SSFO was expressed in calcium/calmodulin-dependent protein kinase II alpha-positive projection neurons in the mPFC, and rsfMRI was used to quantify functional connectivity changes elicited by SSFO activation in the mPFC ( Figure 3E ). SSFO activation increased functional connectivity between the mPFC target and a network of structures, including the ventral striatum, nucleus accumbens, orbitofrontal cortex, anterior cingulate cortex, and thalamus ( Figure 3E ), qualitatively similar to many of the areas exhibiting increased connectivity in subtypes 3 and 4. SSFO modulation of mPFC projection cells was also sufficient to drive anhedonia-like behavior in the sucrose preference test (Figure 3F, G) .
Importantly, this approach also provides a means of testing how circuits interact to produce anhedonic behavior. Ferenczi et al. (55) went on to show that mPFC and the VTA compete to influence processing in striatum. VTA stimulation drove a striatal BOLD response that predicted reward-seeking behavior, whereas SSFO modulation of mPFC excitability suppressed the striatal response to VTA stimulation and disrupted reward processing. Of course, these findings do not necessarily indicate that the same mechanism is involved in driving anhedonic behavior in subtypes 3 and 4. Rather, they show that this particular pattern of frontostriatal hyperconnectivity, elicited by increasing the excitability of mPFC projection neurons, is sufficient to disrupt reward-seeking behavior. Future studies could test whether these subtypes are associated with hyperexcitability in mPFC; with deficits in striatal reward reactivity; and with abnormal interactions between VTA, mPFC, and striatum. Likewise, new viral tools for targeting opsin expression to topologically defined projection neuron subtypes with increased ease and efficiency (90) (91) (92) will enable more targeted investigations that modulate connectivity between specific nodes in this frontostriatal network.
The example in Figure 3 illustrates one approach to formulating hypotheses about candidate circuits for optogenetic study, based on qualitatively similar connectivity alterations that co-occur with specific symptoms across subtypes. However, candidate circuits could also be identified in a data-driven way, especially with larger sample sizes. Indeed, multiview, latent-variable methods such as RCCA are well suited to this purpose, as reliable latent variables underlying brain-behavior correlations and discovered by RCCA suggest targets for optogenetic interrogation in rodent experiments, which could test whether symptom dimensions can indeed be dissociated by modulating the candidate neural targets. Including sparsity constraints as in the study by Xia et al. (21) may further refine candidate targets for optogenetic interrogation using RCCA.
Caveats and Limitations
It is also worth noting some important caveats associated with this approach. First, Figure 2A underscores how CCA has a tendency to overfit when combined with a feature selection step. Therefore, when screening is used to preselect features for further analysis, careful training and test validation are necessary to generate models that perform well in held-out data and to avoid overfitting. Second, the feature selection approach used here is adequate for identifying stable and robust associations between RSFC features and clinical symptoms, but other approaches (e.g., nonlinear multiview and/or sparse methods) could yield superior results.
Third, these approaches may be highly sensitive to clinical sample characteristics (e.g., distinct circuit mechanisms may be at play in active depression, depression in remission, and various anxiety disorders) as well as to medication status, data quality, head motion, and other sources of global signal artifacts. Therefore, it is important to optimize and validate preprocessing methods and other data quality controls based on the goals of a given study. Medication status is an especially important issue: Our sample was treatment resistant, and most subjects were taking at least one psychiatric medication at the time of their scans (Supplemental Table S1 ). The subtypes did not differ by medication status, indicating that the subtyping results were not likely driven by medication usage per se (18) . However, several studies indicate that antidepressants and other psychotropic medications have significant and varied effects on RSFC measures (93) (94) (95) (96) (97) (98) . Therefore, future studies will be needed to systematically characterize medication effects on resting-state networks and to evaluate the extent to which our results would generalize to unmedicated patients, non-treatment-resistant patients, and first-episode patients.
Fourth, categorical subtyping is just one approach to parsing diagnostic heterogeneity, and the four-cluster solution in Figure 3B is not the only solution. Rather, as discussed in our prior work (18) , this four-cluster solution was stable and clinically useful (predicting clinical symptoms and treatment response), but also most likely constrained by features of the subtype discovery dataset, especially sample size and the available clinical data. Item-level HAMD responses provide a relatively coarse, ordinal rating of a limited set of depressive symptoms, and future studies will surely benefit from incorporating more precise rating scales designed to measure specific constructs as well as objective behavioral measures. Likewise, although a model anchored in categorical subtypes provides a familiar and clinically useful heuristic for clinicians to parse diagnostic heterogeneity, other methods might be superior. One alternative approach that warrants further ofMRI for Defining Circuit Mechanisms in Depression examination would substitute a multidimensional rating system for categorical subtype diagnoses.
Finally, although we focus here on ofMRI, this approach has some limitations, and other approaches should also be considered. First, it is unclear whether RSFC measures are interpretable in the same way in rodents and primates. A growing body of work highlights qualitative cross-species similarities (99) , including a reliable RSFC signal that correlates with low-frequency (delta) power (100,101); robust resting-state functional networks (67, (102) (103) (104) (105) ; and a neuroanatomically similar default mode network in both rats and mice (103, 106) . However, cross-species differences are also evident. For example, the rodent default mode network lacks a neuroanatomical correlate of the primate posterior cingulate areas 23 and 31 (99, 106) . Likewise, other rsfMRI studies comparing the topology of the mouse, macaque, and human brain have identified reliably conserved properties (e.g., rich club connectivity) but also important differences (e.g., the probability that highly connected hubs are connected to other hubs) (106) . Second, some brain circuits in primates may not have clear homologues in rodents. For example, the PFC exhibits a host of cytoarchitectonic, topological, and molecular differences in rodents versus primates (107) , and multimodal association cortex occupies a much larger proportion of the human brain (108) . Third, rodent models of human behavior are inherently limited to behaviors that are well conserved across species (109) , and even superficially similar behaviors and cognitive processes may be implemented by different mechanisms across species (110, 111) . Consequently, studies drawing parallels between brain circuits and behavior in rodents versus humans must be interpreted with care, and some human brain circuits and behaviors are simply not well modeled in the mouse. In these cases, other approaches, such as concurrent transcranial magnetic stimulation/fMRI (112) (113) (114) and new methods for analyzing interactions between brain lesions and their relationship to behavior (115) , may be superior for testing causality in the human brain directly (33).
Conclusions
The above caveats notwithstanding, the results in Figures 1-3 and the accompanying review highlight the potential for integrating clinical neuroimaging analyses with ofMRI approaches to formulate and test hypotheses regarding latent, subtypespecific mechanisms underlying depression-related behavior. RCCA can be used to discover robust and stable latent associations between functional connectivity and behavior, linking specific circuits with specific clinical symptom combinations that may be differentially involved in individual patients with MDD. ofMRI, in turn, provides a powerful tool for testing hypotheses derived from clinical neuroimaging data; for implicating specific patterns of network dysfunction as causal mechanisms, not just functional correlates; and for isolating the contributions of specific network nodes and circuits and studying their interactions.
